Damai Santosa

Dr. Damai Santosa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
EPEko A. Pangarsa
Eko A. Pangarsa
DRDaniel Rizky
Daniel Rizky
KTKevin Tandarto
Kevin Tandarto
BSBudi Setiawan
Budi Setiawan
DSDamai Santosa
Damai Santosa
CSCatharina Suharti
Catharina Suharti
Background: Breast cancer is quite frequent all around the world. This disease was responsible for an estimated 2.1 million malignancies in 2022, making it the seventh-highest cause of cancer deaths globally. A multidisciplinary team (MDT) care policy was developed in the United Kingdom (UK) in 1995 to enhance the quality of care for cancer patients. The purpose of this systematic review and meta-analysis study is to assess the effects of MDT on breast cancer survival rates. Methods: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. Systematic search was conducted in several international databases including Google Scholar, PubMed, EBSCOhost, and Proquest from 2012 to 2022. The authors used RevMan 5.4 to do the meta-analysis of the pooled hazard ratio. Newcastle–Ottawa Scale to measure the risk of bias. Newcastle–Ottawa Scale evaluated participant selection, comparability, and reporting of results using eight subscale items. Egger’s test funnel plot was used to assess the potential publication bias for this study. Results: A total of 1187 studies were identified from research database. The authors found a total of six studies from six different countries (China, the UK, Taiwan, Australia, Africa, and France) included for this study. Based on the meta-analysis of the pooled hazard ratio of the included studies, the authors found that the overall effect size of the study was 0.80 (CI 95%: 0.73–0.88). Conclusions: Breast cancer patients who participated in well-organized MDT discussions had a greater survival rate than those who did not.

Verified
Journal Article
Open access
DSDamai Santosa
Damai Santosa
CSCatharina Suharti
Catharina Suharti
IRIgnatius Riwanto
Ignatius Riwanto
EDEdi Dharmana
Edi Dharmana
EPEko Adhi Pangarsa
Eko Adhi Pangarsa
SHSocharyo Hadisapurto
Socharyo Hadisapurto
Background: The treatment for ineligible transplant multiple myeloma is melphalan prednisone. Curcumin has an anti-inflammatory and antiangiogenesis in cancer-directed to nuclear factor-kappa B (NF-kB) pathway. Interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and lactate dehydrogenase (LDH) were also involved in the pathogenesis of myeloma. No clinical study has evaluated the efficacy of curcumin in myeloma patients. To evaluate the efficacy of curcumin as adjuvant into melphalan prednisone in myeloma patients Methods: 33 myeloma patients at Dr. Kariadi General Hospital, Semarang, Indonesia during 2016-2017 were randomly assigned single-blindedly into MPC (n=17) and control group (n=16). The MPC group was treated with melphalan 4 mg/m2, prednisone 40 mg/m2 for 7 days, and curcumin 8 gram daily for 28 days. The MP control group was treated with melphalan, prednisone, and placebo. The primary endpoint was the overall remission. Preand post-treatment was examined for NF-kappa B, VEGF, TNF-alpha, IL-6, LDH, and CRP levels All data analyses were per protocol. Results: There was a significant difference in overall remission between the MPC and MP control groups [75%vs 33.3%, x(2) =6.89, P:0.009]. A significant decrease of NF-kappa B, VEGF, TNF-alpha levels were shown in the MPC group compared with the MP control group. There was a significant decrease in IL-6 levels in a subgroup analysis of the MPC group. TNF-alpha levels had a significant correlation with remission [OR=1.35; (95%CI=1.03-1.76); P=0.03]. Conclusion: Curcumin has an efficacy in improving overall remission and decreasing NF-kappa B, VEGF, TNF-alpha, and IL-6 levels in myeloma patients.

1 July 2022 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
BSBudi Setiawan
Budi Setiawan
WBWidi Budianto
Widi Budianto
TSTri Wahyu Sukarnowati
Tri Wahyu Sukarnowati
DRDaniel Rizky
Daniel Rizky
EPEko Adhi Pangarsa
Eko Adhi Pangarsa
CSCatharina Suharti
Catharina Suharti
Background: Deep vein thrombosis (DVT) is a common complication and the second leading cause of death in cancer patients. Pro-inflammatory stimuli in the cancer microenvironment induce nuclear factor kappa B (NF-κB) signaling pathway that plays an integral role in immunothrombosis mechanism. Objective: To investigate the role of inflammatory and coagulation biomarkers in the development of DVT in cancer patients with high risk of thrombosis (Khorana score ≥ 2). Subjects and methods: This study was a cross-sectional study at Dr. Kariadi General Hospital. The serum levels of proinflammatory cytokines, ie, NF-κB, interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and coagulation biomarkers, ie, tissue factor (TF), prothrombin fragment F1+2 (F1+2), fibrinogen and D-dimer were measured in newlydiagnosed cancer patients with a highrisk of thrombosis. Color duplex sonography was used for DVT screening. Results: From January to November 2021, there were 83 eligible patients. DVT was confirmed in 8 subjects (9.63%). Univariate analysis revealed a significant difference between the median age of patients with DVT compared to non-DVT patients, 49.5 years (range: 23– 60 years) and 42 years (range: 19– 60 years), with p=0.046. D-dimer level was higher in DVT patients [(6.020 μg/L, range 2.090– 20.000) vs (1.940 μg/L, range 270– 20.000), p=0.005]. Multivariate analysis revealed age and D-dimer were significantly correlated with DVT incidence. In all patients, there were significant positive correlations between several inflammatory and coagulation activation parameters, which were IL-6 with D-dimer and F1+2, CRP with F1+2 and D-dimer as well as TNF-α with F1+2. However, these findings were not shown in DVT patients. Conclusion: In cancer patients with a high risk of thrombosis, age and D-dimer level are the significant variables towards the incidence of DVT. In patients with DVT, there was no significant correlation between inflammatory and coagulation activation parameters.

1 September 2020 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
BSBudi Setiawan
Budi Setiawan
RRRosalina Rosalina
Rosalina Rosalina
EPEko Adhi Pangarsa
Eko Adhi Pangarsa
DSDamai Santosa
Damai Santosa
CSCatharina Suharti
Catharina Suharti
Background: Deep vein thrombosis (DVT) is a frequent complication in cancer patients and is the second leading cause of death. The high level of C-reactive protein (CRP) is an acute phase reactant that induces tissue factor (TF) expression in monocytes, smooth muscle cells, and endothelial cells. The CRP level positively correlates with the incidence, extension, and volume of thrombus. TF expression triggers the coagulation system including the formation of thrombin and circulating fibrin such as prothrombin fragment 1+2 (F1 + 2) and D-dimer. Objective: To determine the diagnostic value of high-sensitivity (hs)-CRP, D-dimer, and Wells score combination to predict the incidence of DVT on clinically suspected DVT (Wells score ≥ 2) cancer patients. Subjects and Methods: This study was a cross-sectional study on a diagnostic test to determine the diagnostic value of hs-CRP and D-dimer for early detection of DVT on clinically suspected DVT (Wells score ≥ 2) cancer patients. It was conducted in Dr. Kariadi Hospital, Semarang Indonesia on 35 subjects. The diagnosis of DVT was confirmed by color duplex sonography. The diagnostic accuracy of combination of hs-CRP, D-dimer, and Wells score was analyzed by logistic regression. Results: DVT was confirmed in 10 subjects (28,6%). The cut-off point of hs-CRP levels for probable DVT was ≥ 51.05 mg/L and for D-dimer was ≥ 5030 μg/L. The median levels of both variables were higher in the subjects with DVT compared with the subjects without DVT, but it was not statistically significant. The combination of hs-CRP (≥ 51.05 mg/L), D-dimer (≥ 5030 μg/L), and Wells score ≥ 3 had the high accuracy (94.1%) to predict the incidence of DVT compared with hs-CRP (65.0%), D-dimer (54.7%), and combination of hs-CRP and D-dimer (71.0%). Conclusion: The combination of hs-CRP (≥ 51.05 mg/L), D-dimer (≥ 5030 μg/L), and Wells score ≥ 3 can predict the incidence of DVT in cancer.

1 October 2024 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
YAYusuf Aminullah
Yusuf Aminullah
ZNZulfikar Naftali
Zulfikar Naftali
DSDamai Santosa
Damai Santosa
YPYan Wisnu Prajoko
Yan Wisnu Prajoko
MAMahalul Azam
Mahalul Azam
HSHertanto Wahyu Subagyo
Hertanto Wahyu Subagyo
Background: Superoxide dismutase (SOD) can be decreased and malondialdehyde (MDA) can be increased in patients with head and neck cancer (HNC) as a result of reactive oxygen species (ROS) brought on by cisplatin. Astaxanthin is one of the external antioxidants required to combat ROS by raising SOD and lowering MDA. The purpose of this study is to demonstrate that astaxanthin can raise SOD and lower MDA in patients with HNC caused by cisplatin. Methods: 42 research subjects were randomly assigned to two groups in a double-blind, randomized controlled trial pre-post test design. Astaxanthin 4 mg BID was administered to the treatment group, whereas a single dosage of 500 mg of vitamin C and 250 mg of vitamin E IU was given to the control group. According to the Mann Whitney test, if p < 0.05, there is a significant difference in the delta of the decrease in SOD and MDA levels between the astaxanthin and vitamin C & E groups. Results: There were 42 research subjects, with a mean age of 48.2 years, a 2:1 male to female ratio, 23 (54.8%) with nasopharyngeal cancer, 32 (76.2%) with stage IV, 14 (33.3%) with cycle IV, 24 (57.1%) with paclitaxel-Cisplatin, 31 (73.8%) with Eastern Cooperative Oncological Group (ECOG) I, and 31 (73.8%) with Normal Body Mass Index. While there was a substantial drop in MDA (p=0.000), there was no significant difference in the delta reduction in SOD (p=0.443). Conclusion: Patients with HNC who receive cisplatin chemotherapy can have an increase in SOD and a decrease in MDA after receiving astaxanthin for 21 days.

13 December 2021 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
DSDamai Santosa
Damai Santosa
MSMuchlis A. U. Sofro
Muchlis A. U. Sofro
FAFarida
Farida
NNNurvita Nindita
Nurvita Nindita
EPEko A. Pangarsa
Eko A. Pangarsa
CSCatharina Suharti
Catharina Suharti
Background: In this report, we describe a very challenging case of a patient with secondary Evans syndrome caused by severe coronavirus disease 2019 infection in a pregnant full-term woman. Case presentation: A 29-year-old full-term pregnant Indonesian woman presented with gross hematuria, dry cough, fever, dyspnea, nausea, anosmia, and fatigue 5 days after confirmation of coronavirus disease 2019 infection. Laboratory examinations showed very severe thrombocytopenia, increased indirect bilirubin, and a positive direct Coombs’ test. From peripheral blood, there was an increased number of spherocytes, which indicated an autoimmune hemolytic process. Antinuclear antibody and anti-double-stranded DNA test results were negative, and her virology serological markers are also negative for human immunodeficiency virus, cytomegalovirus, and hepatitis B and C. Despite aggressive treatment with platelet transfusion, high-dose steroid, and thrombopoietin receptor agonists, the platelet count did not recover, and a speculative cesarean delivery had to be done with a very low platelet count.